Scientific article

Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults

Published inExpert review of clinical immunology, vol. 17, no. 1, 5-13
Publication date2021-01
First online date2020-12-07

Introduction: Guselkumab is a subcutaneously administered human monoclonal antibody, selectively blocking IL-23 through binding to its p19 subunit. It was initially approved for the treatment of patients with moderate-to-severe plaque-psoriasis who are candidates for systemic therapy or phototherapy. Pubmed and Embase databases were searched for publications, using the following search terms: psoriasis, psoriatic arthritis, guselkumab, risankizumab, tildrakizumab, p19, interleukin 23, guidelines, treatment recommendations, DISCOVER, ECLIPSE, and VOYAGE.

Areas covered: Accumulating evidence suggests that the IL-23/Th17 pathway is important in the pathogenesis of both psoriasis and psoriatic arthritis. Following a successful development program in psoriasis, guselkumab was evaluated for its efficacy and safety in psoriatic arthritis in a comprehensive clinical trial program, comprising one phase-2 study and two phase-3 studies (DISCOVER-1 and -2). Complementary data on pharmacokinetics and safety exist from pre-clinical experiments and pooled analyses from two long-term studies in psoriasis (VOYAGE-1 and -2). Based on the DISCOVER-1 and -2 data, guselkumab was approved by the FDA for the treatment of active psoriatic arthritis in 2020.

Expert opinion: Guselkumab is the first selective IL-23 inhibitor approved to treat adults with active psoriatic arthritis, broadening therapeutic options in the field through a novel mode of action.

  • Guselkumab
  • Interleukin-23
  • P19
  • Psoriasis
  • Psoriatic arthritis
  • Risankizumab
  • Tildrakizumab
  • Animals
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Arthritis, Psoriatic / drug therapy
  • Arthritis, Psoriatic / immunology
  • Humans
  • Interleukin Inhibitors / pharmacology
  • Interleukin Inhibitors / therapeutic use
  • Interleukin-23 / antagonists & inhibitors
  • Severity of Illness Index
  • Treatment Outcome
Citation (ISO format)
BOEHNCKE, Wolf-Henning, BREMBILLA, Nicolo, NISSEN, Michael John. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults. In: Expert review of clinical immunology, 2021, vol. 17, n° 1, p. 5–13. doi: 10.1080/1744666X.2020.1857733
Main files (1)
Article (Published version)
ISSN of the journal1744-666X

Technical informations

Creation03/09/2022 6:53:06 AM
First validation05/23/2023 11:01:51 AM
Update time05/23/2023 11:01:51 AM
Status update05/23/2023 11:01:51 AM
Last indexation02/01/2024 10:07:45 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack